Limited impact of EU Paediatric Regulation on Finnish clinical trials highlights need for Nordic collaboration

被引：6

作者：

Korppi, Matti ^{[1
,2
]}

Lepola, Pirkko ^{[3
]}

Vettenranta, Kim ^{[4
]}

Pakkala, Seppo ^{[5
]}

Hoppu, Kalle ^{[4
,6
,7
]}

机构：

[1] Tampere Univ, Tampere Ctr Child Hlth Res, Tampere 33014, Finland

[2] Univ Hosp, Tampere, Finland

[3] Tampere Univ, Finnish Investigators Network Pediat Med, Tampere Ctr Child Hlth Res, Clin Res Inst Helsinki Univ Cent Hosp Ltd, Tampere 33014, Finland

[4] Hosp Dist Helsinki & Uusimaa HUS, Hosp Children & Adolescents, Helsinki, Finland

[5] Clin Res Inst Helsinki Univ Cent Hosp Ltd, Helsinki, Finland

[6] Univ Helsinki, Dept Clin Pharmacol, SF-00250 Helsinki, Finland

[7] Helsinki Univ Cent Hosp, Poison Informat Ctr, Helsinki, Finland

来源：

ACTA PAEDIATRICA | 2013年 / 102卷 / 11期

关键词：

Clinical trial; EU regulation; Paediatric medicines; Research network; CHILDREN RESEARCH NETWORK; MEDICINES; GLOBALIZATION; LABEL; WARDS;

D O I：

10.1111/apa.12372

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

The Finnish Investigators Network for Paediatric Medicines (FINPEDMED) was established in 2007, to meet the expected increase in paediatric clinical trials following the new EU Paediatric Regulation. Between 2007 and 2012, FINPEDMED received 91 trial requests, 18 trials were started, and in 24 cases, Finnish investigators were not selected by sponsors. ConclusionThis experience from Finland highlights the need for Nordic collaboration to increase expertise, recruitment base and attractiveness for sponsors.

引用

页码：1035 / 1040

页数：6

共 50 条

[31] "If you build it, they will come": the convergence of funding, research and collaboration in paediatric brain cancer clinical trials
Hansford, Jordan
Valvi, Santosh
de Boer, Jasper
McCowage, Geoff
Govender, Dinisha
Kirby, Maria
Ziegler, David
Manoharan, Neevika
Hassall, Timothy
Wainwright, Brandon
Alvaro, Frank
Wood, Paul J.
Eisenstat, David
Quang, Dong Anh Khuong
Jenkins, Misty
Dun, Matthew
Laughton, Stephen J.
Endersby, Raelene
Dodgshun, Andrew
Gottardo, Nicholas
MEDICAL JOURNAL OF AUSTRALIA, 2024, 221 (10) : 520 - 523
[32] An EU Comparative Analysis of the Regulation of Clinical Trials Supervisory Bodies in the Aftermath of Regulation 536/2014
de Miguel Beriain, Inigo
Chortara, Theodora
Duardo-Sanchez, Aliuska
Feeney, Oliver
Felzmann, Heike
Fernandez de Uzquiano, Emma
Lievevrouw, Elisa
Marelli, Luca
Mattsson, Titti
Herrmann, Janne Rothmar
Minssen, Timo
Pulice, Elisabetta
Raposo, Vera Lucia
Robienski, Jurgen
Penasa, Simone
Van Hoyweghen, Inc
EUROPEAN PUBLIC LAW, 2020, 26 (02): : 307 - 329
[33] Medicinal studies in palliative care: impact of the EU clinical trials directive
Spathis, Anna
PALLIATIVE MEDICINE, 2007, 21 (01) : 60 - 61
[34] Phase I studies in EU: due change in compliance and transparency under the EU clinical trials regulation
Christian Martin De Mey
European Journal of Clinical Pharmacology, 2022, 78 : 1047 - 1048
[35] Phase I studies in EU: due change in compliance and transparency under the EU clinical trials regulation
De Mey, Christian Martin
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (06) : 1047 - 1048
[36] Clinical Trials Regulation: A Further Step towards Increased Medical Innovation in the EU
Pavlou, Anna
Saurat, Emmanuel
EUROPEAN JOURNAL OF RISK REGULATION, 2015, 6 (04) : 646 - 648
[37] The Proposed EU-regulation on Clinical Trials on Medicinal Products: An Unethical Proposal?
Heringa, Jilles
Dute, Joseph
EUROPEAN JOURNAL OF HEALTH LAW, 2013, 20 (04) : 347 - 362
[38] Redundant trials can be prevented, if the EU clinical trial regulation is applied duly
Kim, Daria
Hasford, Joerg
BMC MEDICAL ETHICS, 2020, 21 (01)
[39] New EU clinical trials regulation Needs a few tweaks before implementation
Westra, Anna E.
Bos, Wendy
Cohen, Adam F.
BMJ-BRITISH MEDICAL JOURNAL, 2014, 348
[40] Redundant trials can be prevented, if the EU clinical trial regulation is applied duly
Daria Kim
Joerg Hasford
BMC Medical Ethics, 21

← 1 2 3 4 5 →